Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Assets (2016 - 2025)

Sunshine Biopharma's Non-Current Assets history spans 11 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 29.79% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 29.79%, while the annual FY2025 figure was $3.2 million, 29.79% down from the prior year.
  • Non-Current Assets reached $3.2 million in Q4 2025 per SBFM's latest filing, down from $3.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.7 million in Q1 2025 to a low of $1642.0 in Q2 2022.
  • Average Non-Current Assets over 5 years is $2.1 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: plummeted 87.82% in 2022, then surged 140662.06% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $7061.0 in 2021, then surged by 27254.68% to $1.9 million in 2022, then grew by 27.2% to $2.5 million in 2023, then soared by 86.98% to $4.6 million in 2024, then fell by 29.79% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Non-Current Assets are $3.2 million (Q4 2025), $3.5 million (Q3 2025), and $4.1 million (Q2 2025).